Pyridoxal-5'-phosphate
Pyridoxal-5'-phosphate has been studied in 6 papers since 2017: 2 observational studies in people, 4 in animals; 2 in the past year. The newest paper, Feb 11, 2026: “Plasma vitamin profiles and their associations with metabolic health and mental wellbeing in midlife Asian women”.
See all 16 papers on pyridoxal-5'-phosphate
At a glance
The findings reach people, from one lab or study. 2 independent labs in 3 countries; 9 trials, none about aging, 5 with no results posted.
“Thiamine monophosphate, pyridoxal-5'-phosphate, and cholecalciferol showed a positive association with favourable metabolic health outcomes such as reduced fasting insulin, increased HDL-cholesterol and reduced MetS scores.”
None of its findings points the other way.
- 2 independent labs in 3 countries
- 9 trials, none about aging, 5 with no results posted
- Funders: National Research Foundation of Ukraine and others
- 1 of 13 findings with company ties
- 6 of 9 trials sponsored by its developers
- Humans2
- Animals4
What did studies of pyridoxal-5'-phosphate find?
9Studies of pyridoxal-5'-phosphate measured 9 outcomes; the most studied are oxidative stress and ROS signaling (3 studies) and hydrogen sulfide (2).
Oxidative stress and ROS signaling
downin rats3
3 studies
Oxidative stress and ROS signaling
downin rats3
Pyridoxal-5'-phosphate decreases oxidative stress and ROS signaling in rats.
“PLP significantly reduced the formation of superoxide, malondialdehyde, diene conjugates”
Animalsper osheart0.7 mg per kg2 weeksn = 20
European journal of clinical investigation
Pyridoxal-5'-phosphate decreases oxidative stress and ROS signaling in old rats.
“PLP significantly reduced diene conjugate content, hydrogen peroxide and peroxynitrite generation rates, and iNOS and arginase activity in the aortic tissue of old rats.”
Animalsin old ratsaorta0.7 mg/kg body mass once a day2 weeksmales
Canadian journal of physiology and pharmacology
Pyridoxal-5'-phosphate decreases oxidative stress and ROS signaling in rats.
“Under these conditions, the following indicators of oxidative stress were significantly decreased in heart and aorta tissues: superoxide generation rate (·0(2)(-)) and hydroxyl (·OH) anion radicals”
Animalsheart and aorta
Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)
Hydrogen sulfide
upin rats2
2 studies
Hydrogen sulfide
upin rats2
Pyridoxal-5'-phosphate increases hydrogen sulfide in old rats (restored to levels detected in adults).
“PLP restored endogenous H2S and low molecular weight S-nitrosothiol levels in old rat aorta to the levels detected in adults.”
Animalsin old ratsaorta0.7 mg/kg body mass once a day2 weeksmales
Canadian journal of physiology and pharmacology
Pyridoxal-5'-phosphate increases hydrogen sulfide in rats.
“The administration of pyridoxal-5-phosphate as cofactor of H(2)S synthesizing enzymes restored endogenous H(2)S level and redox state in the heart and aorta tissues.”
Animalsheart and aorta
Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994)
Fatty acid β-oxidation
upin rats1
1 study
Fatty acid β-oxidation
upin rats1
Pyridoxal-5'-phosphate increases fatty acid β-oxidation in rats.
“PLP treatment increased glucose consumption and utilization, decreased lipid transport into the cells, but increased fatty acid β-oxidation, providing sufficient energy.”
Animalsheart
Mitochondrion
Oxidative phosphorylation
upin rats1
1 study
Oxidative phosphorylation
upin rats1
Pyridoxal-5'-phosphate improves oxidative phosphorylation in rats.
“We demonstrated improvement of mitochondrial bioenergetic functions, inhibition of mPTP opening after PLP administration.”
Animalsheart
Mitochondrion
Cardiac function
upin rats1
1 study
Cardiac function
upin rats1
Pyridoxal-5'-phosphate improves cardiac function in rats.
“An ECG study showed a significant improvement in cardiac function in PLP-treated old rats.”
Animalsheart
Mitochondrion
CTH
upin rats1
1 study
CTH
upin rats1
Pyridoxal-5'-phosphate increases CTH in rats.
“PLP restored mRNA levels of CSE, 3-MST and UCP3 genes, and H2 S content”
Animalsper osheart0.7 mg per kg2 weeksn = 20
European journal of clinical investigation
Reperfusion injury
downin rats1
1 study
Reperfusion injury
downin rats1
Pyridoxal-5'-phosphate prevents reperfusion injury in rats after ischemia.
“prevented reperfusion disturbances of the heart function after ischemia”
Animalsafter ischemiaper osheart0.7 mg per kg2 weeksn = 20
European journal of clinical investigation
iNOS
downin rats1
1 study
iNOS
downin rats1
Pyridoxal-5'-phosphate decreases iNOS in old rats.
“PLP significantly reduced diene conjugate content, hydrogen peroxide and peroxynitrite generation rates, and iNOS and arginase activity in the aortic tissue of old rats.”
Animalsin old ratsaorta0.7 mg/kg body mass once a day2 weeksmales
Canadian journal of physiology and pharmacology
Endothelium-dependent vasorelaxation
upin rats1
1 study
Endothelium-dependent vasorelaxation
upin rats1
Pyridoxal-5'-phosphate improves endothelium-dependent vasorelaxation in old rats; acetylcholine-induced relaxation of aortic rings (47.7% ± 4.8% versus 18.4% ± 4.1% in old rats).
“PLP also greatly improved acetylcholine-induced relaxation of old rat aorta (47.7% ± 4.8% versus 18.4% ± 4.1% in old rats, P < 0.05)”
Animalsin old rats; acetylcholine-induced relaxation of aortic ringsaorta0.7 mg/kg body mass once a day2 weeksmales
Canadian journal of physiology and pharmacology
What is pyridoxal-5'-phosphate linked with?
1Studies link pyridoxal-5'-phosphate with metabolic syndrome score.
Metabolic syndrome score
downin humans1
1 study
Metabolic syndrome score
downin humans1
Pyridoxal-5'-phosphate is associated with metabolic syndrome score in humans (Asian women).
“Thiamine monophosphate, pyridoxal-5'-phosphate, and cholecalciferol showed a positive association with favourable metabolic health outcomes such as reduced fasting insulin, increased HDL-cholesterol and reduced MetS scores.”
HumansAsian womenplasmafemalesn = 662
Scientific reports
Has pyridoxal-5'-phosphate been tested in people?
0 of 9 about agingYes: 2 observational studies in people have been published, and 9 trials are registered.
In trials
Phase 3Completed2 trials
Phase 3Completed2 trials
Phase 3Completed2 trials
Pyridox am ine 5 phosphate oxidase deficiency
Phase 3Active, not recruiting2 trials
Phase 3Completed2 trials
Phase 2Completed1 trial
All 12Fewer
Readouts due
- Sep 2027
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
Phase 3Active, not recruiting
Stopped
NCT00917293TerminatedSchizophrenia
modified formulation under investigation
Who is developing pyridoxal-5'-phosphate?
1 company: Medicure.
- Companies
- MedicurePhase 3pyridox am ine 5 phosphate oxidase deficiency
Trial sponsors
Company6 trialsPhase 34,138 people
1 trialEarly phase 19 people
1 trial44 people